ArchiveDifficulty in research and development(R&D) of pediatric drugs is a global problem. The high difficulty of R&D, high costs and long cycle of pediatric drugs, as well as the low market returns compared with the adult medicines because of the short medication cycle, aggravate the inactive R&D situation of pediatric drugs. In order to encourage the R&D of pediatric drugs in China, various countries have adopted many measures to acclerate the R&D of pediatric drugs. This paper summarizes and analyzes the special policies and related technical guidelines issued by US, EU, Japan and China to accelerate the review and approval of pediatric drugs, which will serve as a referance for Chinese pediatric drugs developers and the follow-up government regulation and policy makers.
The goal of pediatric drug development is to provide safe, effective, quality controllable and suitable for children of different ages. It is common to expand pediatric drug applications to optimize improved new drugs with obvious clinical advantages based on drugs with known active ingredients. Based on investigational new drug(IND) application information accepted by the Center for Drug Evaluation from March 4, 2016 to June 30, 2022, this paper introduced the application and review of 2.2 category improved new chemical drugs for pediatric. Meanwhile, the application items approved and failed were sorted out, and the concerns of assessment to the purpose of the project were discussed to provide a reference for the application of 2.2 category improved new drugs.
Since the reform of drug evaluation and approval system in 2015, China has established various policies for imported drugs and pediatric drugs. Imported drugs are of great value in satisfying pediatric clinical needs in China. This study aimed to understand the registration situation of imported drugs for children and provide policy suggestions through analysis on imported drugs approved for children since 2019.
Refer to the EU Guidelines for pharmacovigilance of pediatric medicines, this paper analyzed the characteristics of adverse reactions in pediatric clinical trials and pediatric populations, and the main points of pharmacovigilance in pediatric populations. The pediatric population is in the stage of growth and development. The frequency and nature of adverse reactions are different from that of adults. According to the physiological and pathological characteristics of the pediatric population, they should be distinguished in terms of adverse reaction reporting and treatment, risk control, signal management, regular safety reports, and post-marketing research. Taking into account the current situation of pharmacovigilance construction during clinical trials in China, accelerate the establishment of a pharmacovigilance system for pediatric clinical trials and strengthen the protection of subjects in pediatric populations.
The FDA and EMA regulatory policies for pediatric drugs are introduced from the aspects of regulatory policy establishment, implementation scope of pediatric study plan, review time limit and application requirements, some suggestions are put forward to further improve pediatric drug regulation in China. In combination with the revision of “Regulations for the Implementation of the Drug Administration Law” and the current situation of drug review resources, some recommendations are listed as follows: further improving the legal and regulatory system for the supervision of pediatric drugs, formulating relevant working procedures for pediatric study plan in line with the actual drug review condition in China, further supplementing the technical guidelines for pediatric drugs, guiding and standardizing research and development process for pediatric drugs of manufacturing enterprises, promoting pediatric drug innovative process, and effectively solving the unmet clinical needs of pediatric population in China.
In recent years, paediatric pharmaceutical has become a hotspot of drug development and clinical trials in paediatric population have gradually increased. The conduct of juvenile animal studies(JAS) should be considered only when previous nonclinical and clinical data are insufficient to support paediatric clinical trials. A JAS is designed to address safety concerns that cannot be adequately addressed in other nonclinical studies or paediatric clinical trials, including potential long-term safety effects. The ICH S11 Nonclinical safety testing in support of development of pediatric pharmaceuticals was issued in 2020. This article discusses considerations of JAS, combining with ICH S11 guidance and cases analysis, aiming to provide information for pediatric pharmaceutical development in China.
Based on the analysis of the 2020 edition of Chinese Pharmacopoeia(Part I), the National Essential Drug Catalogue(2018 edition), and the investigational new drug applications of new traditional Chinese medicines(TCMs) for children in recent years, it is concluded that the pharmaceutical preparations of TCMs for children have the some problems, such as lack of pediatric drug fomulations, insufficient dosage forms, narrow range of therapeutic areas, and lack of safety data of excipients for children. According to the basic requirements in drug product technical review, the paper discusses the general considerations for the research and development of TCMs for children, from the following aspects: the basic requirements of pharmaceutical research of pharmaceutical preparations of TCMs, the characteristics of children's medication, the route of administration and dosage form design, the dosage accuracy, the suitability of packaging systems, the types and dosages of excipients, and quality control. It is hoped to provide some useful references for the development and research of pharmaceutical preparations of TCMs for children.
Based on the characteristics of oral solution for pediatric use, this paper summarizes and analyzes the relevant industry guidelines and guiding principles. In order to improve the quality of oral solution for pediatric use, the pharmaceutical concerns in research, development and evaluation are expounded.
The labelings of medicines lack information and have problems of incomplete and inaccurate descriptions on posology and method of administration for pediatrics. There is an urgent need to issue relevant requirements to provide standardized guidance for posology and method of administration for pediatrics. This paper introduces the main problems of posology and method of administration in the labelings of pediatric medicines, discusses the writing requirement from general consideration, medicine pretreatment, preparation method, and medicine usage instruction, and proposes recommendations for relevant pharmaceutical research. Considerations and suggestions were put forward on the research, development, and supervision of pediatric medicine in China.
Childhood is a critical period for body growth and development. Adequate calcium intake is the basic guarantee for normal growth and healthy development of bones. Thereof, the development and quality control of calcium supplements for children are very important. Taking calcium gluconate tablets, calcium and zinc gluconate oral solution, chewable calcium carbonate tablets, calcium carbonate-vitamin D3 chewable tablets as the examples, aiming to provide the corresponding references for the industry, this paper simply analyzes the relevant considerations on pharmaceutical research of calcium supplements for children from the aspects of raw materials, excipients, packing materials, formulation and process, and quality research.
“Encourage pediatric drugs catalogue(batches 1 - 3)” have been issued by National Health Commission to facilitate the development and accessibility of paediatric medicines. The indications, approval dosage form and reference list drug(RLD) of chemical psychotropic and neuropsychiatric drugs in this catalogue are sorted out. Based on the analysis of specific cases and relevant review reports, some key points of the drug research and development are discussed, and some considerations about pharmaceutical studies are put forward in order to provide certain references for the selected pediatric drugs. It's recommended to take clinical needs into account and conduct further in-depth pharmaceutical studies on dosage form, drug substance and quality control, so as to improve the development of pediatric drugs.
In recent years, China has frequently issued relevant regulations and guiding principles to encourage the development of drugs for children. However, due to the specificity of children, developing child-friendly excipients is a challenge, especially in choosing appropriate excipients for pediatric medicines. In particular, the selection of appropriate excipients for pediatric medicines is often limited due to the lack of safety data. In this paper, the closely concerned antimicrobial agents were taken as an example, and the relevant regulations and technical requirements of China, WHO, EMA, and other authoritative regulatory authorities were sorted out, and the problems that antimicrobial agents for pediatric medicine need to pay attention to and the differences between pediatric medicine and adult drugs and related registration and application requirements were summarized to help drug researchers develop more suitable drugs for pediatric.
Due to the physiological characteristic of the pediatric population, extrapolation of clinical data from the adult population to the pediatric population is a development focus on pediatric medication. Bayesian statistics, as a flexible method to efficiently utilize the occupied early clinical data, is becoming a powerful tool in the extrapolation of efficacy in pediatric medicine. Based on the introducing of pediatric research features, this paper illustrates the basic concepts and framework of Bayesian statistics, introduces power priors, mixed priors and meta-analysis predictive priors, as well as the important role of simulation technology in Bayesian statistics. Then, a case study of multiple sclerosis in a pediatric population using robust meta-analysis predictive priors to borrow historical data from adult population is present. Finally, this paper discusses other fields of Bayesian statistics in pediatric medication extrapolation and the key consideration in clinical development.
The United States has passed legislation to promote the development of pediatric drugs, requiring R&D companies to submit pediatric study plan in the early stage of research and development. The purpose is to allow R&D companies to determine the needs of pediatric applications in the early stage of clinical research. The specific requirements of the US Food and Drug Administration on pediatric study plan, including the research strategy, the timing of the research and the content of the submitted data, can be used as a reference for Chinese R&D enterprises. Research and development companies can plan pediatric research as early as possible in early clinical research and development, effectively utilize the strategy of extrapolation from adults to children, communicate with regulatory agencies as early as possible, improve research and development efficiency, and speed up the marketing of pediatric drugs.
Dose selection is a key aspect of pediatric drug development. Getting the right dose for pediatric patients, especially newborns and infants, is critical but poses great scientific, practical, and ethical challenges. In addition, the significant differences in different growth and development stages also have an important impact on pediatric dose selection. On the one hand, adult data have reference significance for pediatric drug dose selection and are an important basis for pediatric drug research design and data analysis. On the other hand, model-informed drug development is widely used in dose exposure-response characterization and optimization of dose selection for pediatric drugs. This paper summarizes and analyzes the experience of pediatric drug dose selection, which will serve as a referance for Chinese pediatric drug developers and the follow-up government regulation and policy makers.
Rivaroxaban granules for oral suspension was approved by FDA in 2021 for the treatment of venous thromboembolism(VTE) and prevention of VTE recurrence in patients under age of 18 years after at least 5 days of initial parenteral anticoagulation treatment. The development of rivaroxaban granules for oral suspension for pediatric indications was based on adult data. Model-informed drug development method was adopted to support the initial dosage selection in pediatric clinical trials, dose adjustment of phase Ⅱ and Ⅲ clinical trials. This paper analyzes the relative pediatric studies and FDA’s evaluation considerations of rivaroxaban granules for oral suspension, and discusses the application of model-informed drug development in pediatric drug development.
Population pharmacokinetics has been widely used in clinical practice, which is an effective method to optimize individualized drug delivery schemes and clinical evaluation of new drugs. This paper introduces the technical system of drug population pharmacokinetics in pediatric population based on the integration of opportunistic sampling approach, micro sample analysis, quantitative pharmacological model of child development and machine learning. The applications of this technical system to research and development of pediatric drugs and individualized treatment are briefly introduced, hoping to promote the process of drug research and development as well as the rational use of medicines in children.
Antiepileptic drugs(AED) are the cornerstone and first-choice of the treatment for childhood epilepsy. However, due to the difficulty of evaluating efficacy by randomized controlled trials in the pediatric population, the development of new AEDs for children is delayed. This paper reviews the evidence, history and current thoughts of applying extrapolation method into the development of pediatric AEDs. Besides, the extrapolation-based strategies for pediatric clinical trial design are also illustrated. The results show that the efficacy of drugs treating focal onset seizures(FOS) currently could be extrapolated from adults to pediatric patients 1 month of age and older. The pediatric extrapolation plans should include: the development of pediatric formulations, the rational design of pediatric pharmacokinetics(PK) study and long-term safety study, as well as model-informed dose selection for antiepileptic drugs in pediatrics.
Respiratory diseases in children, as common diseases with high morbidity, are closely related to the physiological characteristics of respiratory system in children. Chinese patent medicines have obvious advantages and characteristics in the treatment of respiratory diseases in children, but some problems have limited their clinical use. For example, how to accurately quantify the drug dosage is a difficult problem limiting the development of pediatric drugs. Nowadays, the national policies are released to encourage the drug development of pediatric drugs. This paper intends to analyze the research status of Chinese patent medicines for respiratory diseases in children, and put forwards some personal views on this issue, hoping to provide some references for those involved in the development of Chinese patent medicines for the treatment of respiratory diseases in children.
The proposal of “the evidence system for TCM registration evaluation combining TCM theory, experiences in human use and clinical trials” is conducive to the research and development of Traditional Chinese medicine for children. Regarding to the situations encountered in the medical review, this article puts forward some suggestions and considerations from the perspective of clinical review for the reference of development of pediatric drug of TCM.
In recent years, with the progress of tumor immunotherapy and gene modification technology, chimeric antigen receptor T cells(CAR-T) has become a hot topic in drug research and development. CAR-T drugs targeting CD19 have significant therapeutic effects on acute lymphoblastic leukemia(ALL) in children, especially relapsed/refractory ALL with poor efficacy of conventional methods such as chemotherapy and hematopoietic stem cell transplantation. Several CAR-T products have been approved by drug regulatory administration for marketing, but no CAR-T products for children with ALL have been approved in China. This study mainly introduces the current situation of CAR-T products licensed to carry out drug clinical trials in China. Then the clinical needs and the critical elements of drug clinical research and development for acute B-cell lymphocytic leukemia in children is discussed, to provide reference for the design of registered clinical trials of similar products.
Children differ from adults in their tolerance to aversive feelings due to their physical and psychological developmental characteristics. They are also at a relatively higher risk of not taking medications as prescribed when the medication tastes unpleasant. Therefore, sound design and evaluation of the oral sensory features have important clinical significance and value in developing pediatric medications. This article briefly discussed the general considerations for the design and evaluation of the oral sensory features of pediatric medications based on the "Technical Guidance for the Design and Evaluation of the Oral Sensory Features of Pediatric Drugs (Draft)", which was released in June 2022, to draw attention of all parties to the design and evaluation of pediatric medications, evoke discussions, promote relevant research progress, and provide a reference for developing more suitable medicines for children's needs.
Antineoplastics are one of the most active fields in new drug research and development, but there are still obvious deficiencies in the research field of pediatric antineoplastics in China. And pediatric cancer patients have an urgent need for medication. Compared with clinical trials in adults, clinical trials of pediatric population often face more challenges, exacerbating the development dilemma of pediatric drug research and development. In order to encourage the research and development of pediatric antineoplastics in China, policy support should be given to activate the research motivation of manufacturing enterprises. In the process of research and development, attention should be paid to the differences between pediatric tumors and adult tumors, the mechanism research should be strengthened, and the research and development should be determined based on the characteristics and treatment needs of pediatric cancer patients. Meanwhile, we should use adult clinical data to support the development of pediatric antineoplastics, and make full use of quantitative pharmacology and other scientific tools, so as to reduce unnecessary researches in children. We should properly grasp the opportunity to carry out studies in pediatric population, especially in children and adults with comorbidity tumors, and promote the research and development of pediatric antineoplastics as soon as possible. In addition, the special needs of children, such as rational dosage forms and long-term safety, should also be fully considered in the research and development process.